New Market Perspective
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

New Market Perspective

World

Drugmakers at fault over toxic cough syrup, Indonesia court finds

by admin August 23, 2024
August 23, 2024
Drugmakers at fault over toxic cough syrup, Indonesia court finds

An Indonesian court ordered two local companies to pay up to 60 million rupiah ($3,850) to each family whose children died of an acute kidney injury or were seriously injured after consuming toxic cough syrup.

More than 200 children in Indonesia died of the injury and about 120 more survived, some of whom lived with disabilities which led to financial hardships for their parents.

Indonesian courts have cited lax oversight by pharmaceutical companies, including local drugmakers and some suppliers, as well as the country’s food and drugs agency (BPOM), in hearings into the poisonings.

In late 2022, more than 20 families launched a civil suit against the agency, the health ministry, and several companies.

Judges at the Central Jakarta court found a drugmaker and a supplier, Afi Farma and CV Samudera Chemical, at fault in the poisonings, according to a ruling released late on Thursday.

The health ministry and the BPOM were cleared of wrongdoing.

The court ordered the companies to pay the parents who brought the suit compensation of 50 million rupiah for children who died and 60 million rupiah for children who were injured.

Parents had asked for 3.4 billion rupiah for each child that died, and 2.2 billion rupiah for survivors. Indonesia’s 2023 gross domestic product per capita was nearly $5,000, data from the country’s Statistics Bureau shows.

Siti Habiba, the lawyer for the parents, said the families were disappointed by the ruling, as the money was given “as though we were beggars.”

“This breaks a lot of the victims’ hearts,” she said, adding the court ignored the parents’ government oversight concerns by not finding the health ministry and the BPOM at fault.

The court document, posted on its website, did not include reasons for the decision.

Afi Farma’s lawyer Reza Wendra Prayogo told Reuters on Friday the firm was “disappointed” with the civil case ruling and the company was still considering its next legal step.

Last year, a criminal court found East Java-based drugmaker Afi Farma guilty of negligence and jailed officials for not testing the ingredients sent by its supplier.

The syrups contained ethylene glycol (EG), a commonly used chemical in products such as brake fluid and antifreeze. A court document from that criminal case said the EG concentration in the syrups reached as high as 99%, where international standards say only 0.1% of EG is safe for consumption.

The company has repeatedly denied negligence.

Reuters could not immediately contact CV Samudera Chemical, an Indonesian soapmaker, whose toxic ingredient made its way to Afi Farma, according to the court document of the Afi Farma criminal case in 2023.

The World Health Organization said the contaminated medicines had also killed children in Gambia and Uzbekistan in 2022.

This post appeared first on cnn.com

0
FacebookTwitterGoogle +Pinterest
previous post
Why this former Republican presidential candidate is at the Democrats’ 2024 convention
next post
Ukraine’s march into Russia exposes Putin’s crisis management problem

Related Posts

Israeli strike on cafe near Gaza City port...

July 1, 2025

Sudan’s RSF conducts first drone attack on Port...

May 4, 2025

‘Ferocious violence’ accompanied ‘shocking’ levels of abuse at...

September 4, 2024

Putin says West sending troops to Ukraine could...

February 29, 2024

Ecuador president’s war on crime gets a boost...

April 23, 2024

Top of Kharkiv’s giant TV tower crashes to...

April 23, 2024

Voyager 1 is sending data back to Earth...

April 23, 2024

Canada’s election will be an ‘elbows up’ battle,...

March 24, 2025

United Nations report heavily critical of UK’s ‘increasingly...

January 24, 2024

Former Assad security forces hand in weapons to...

December 20, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • White House reveals highest-paid staffers–and 8 taking no salaries

      July 3, 2025
    • Trump $3.3T megabill sets House record for longest vote in history

      July 3, 2025
    • Iran nuclear program set back 2 years after US strikes: Pentagon

      July 3, 2025
    • Airlines secretly sold US travelers’ data to Homeland Security

      July 3, 2025
    • White House reveals highest-paid staffers – and 8 taking no salaries

      July 3, 2025
    • Jeffries stalls Trump’s ‘big, beautiful bill’ for hours after House GOP mutiny breakthrough

      July 3, 2025

    Popular

    • 1

      Top 5 Junior Copper Stocks on the TSXV in 2023

      December 22, 2023
    • 2

      Crypto Market 2023 Year-End Review

      December 22, 2023
    • 3

      Canada Silver Cobalt Begins Drilling at Lowney-Lac Edouard in Quebec, Targeting Nickel-Copper-Cobalt Mineralization

      December 22, 2023
    • 4

      10 Top Oil-producing Countries (Updated 2024)

      October 19, 2024
    • 5

      Top 10 Uranium-producing Countries (Updated 2024)

      April 18, 2024
    • 6

      Powered by rain, this seed carrier could help reforest the most remote areas

      December 19, 2023
    • 7

      A troubling theory about traders profiting from Hamas’ attack on Israel drew much attention. Why it may not be so simple.

      December 13, 2023

    Categories

    • Business (1,397)
    • Investing (3,435)
    • Politics (4,507)
    • World (4,410)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: newmarketperspective.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 newmarketperspective.com | All Rights Reserved